Rerun: Another double digit premium increase. Wal-Mart, can you help me?

August 31st, 2012 by David E. Williams of the Health business blog

The Health Business Blog is taking a break and re-running some posts from 2008. If you’d like to comment, please do so on the original post. What a difference four years makes! My premium is falling for 2012/2013.

It’s that time of year again: when Blue Cross Blue Shield of Massachusetts sends the annual health insurance renewal notice for my boutique health care consulting firm. This year’s increase is 13.3 percent, on top of last year’s 26.3 percent increase and an 11 percent increase the year before. Thanks to the magic of compounding it means the premium has gone up about 60 percent in three years. Health insurance has become a serious burden for us.

There’s not much I can do about it either. The “Alternative Plan Solutions” offered by Blue Cross reduce premiums modestly in exchange for significant cuts in benefits. For example, we could save $147 per month ($1764 per year) by choosing a plan with a $2000 deductible per individual/$4000 per family. That hardly seems worth it since it could end up increasing out of pocket costs and it also means replacing pre-tax premium dollars with after-tax payments toward the deductible. (The plan does not appear to be a true consumer directed plan that could be paired with a Health Savings Account.)

In previous years we’ve reacted to higher premiums by dumbing down the coverage. As a result our office visit co-pays and prescription drug co-pays are high. I recently paid over $100 for the generic version of a covered prescription drug! I’m not inclined to skinny the plan further.

This brings me to a discussion of Wal-Mart. I received a note from Wal-Mart Watch today, taking issue with Wal-Mart’s $4 generic program:

We’d like to take a moment today to applaud two Arkansas state senators for standing up to Wal-Mart. Sen. Percy Malone and Rep. Tracy Pennartz, in a meeting with Wal-Mart’s senior director of health-care policy Joe Quinn, accused the company of “just trying to polish its image” by calling its $4 generics program “real change in health care.” Wal-Mart, long accused of providing stingy benefits for its employees, has been citing its low retail prices as an answer to criticisms of its health care plan.

Rep. Pennartz, for her part, expressed concerns for independent pharmacists across the country, who would face serious difficulties matching Wal-Mart’s low price. Independent businesses are certainly struggling to keep up with Wal-Mart’s pricing, but Pennartz’s concerns reveal a larger point: Wal-Mart’s $4 generics are aren’t an answer to America’s health care problems, they’re a way for Wal-Mart to make more money. Whether that means luring in Medicaid recipients who need cheaper drugs, getting employees to use the company pharmacies for their prescriptions or driving out competing pharmacies, Wal-Mart is only looking out for one thing: itself.

I actually agree with Wal-Mart’s claim that the $4 generic program is true health care reform. If the program is the result of Wal-Mart looking out for itself I say keep it coming! My non-profit health plan and the local non-profit health care systems don’t exactly seem to be solving the health care cost problem despite their public-oriented missions. I hope Wal-Mart keeps ‘looking out for itself’ in the area of health care. If that means applying the same principles to the rest of health care financing and delivery that Wal-Mart’s applied to generics, I’m not going to be upset.

I’m also sympathetic to Wal-Mart when it comes to providing insurance for low-wage workers. A worker making the US minimum wage of $6.55 per hour, working 40 hours per week, 50 weeks per year would make $13,100. By contrast our company’s premium is more than $15,000 per family. And of course that doesn’t count the out-of-pocket payments if someone actually wants to use their insurance.


Posted in Economics, Health plans, Policy and politics | 1 Comment »

Rerun: With medication adherence, more is more

August 24th, 2012 by David E. Williams of the Health business blog

The Health Business Blog is taking a break this week, and re-running some posts from 2008. If you’d like to comment, please do so on the original post.

A new study by health care analytics company, SDI reveals a promising insight on how to drive medication adherence.

[P]rescribers who consistently wrote prescriptions with four or more authorized refills per prescription had patient populations that filled more scripts, on average, than those who authorized fewer refills or whose patients required a new prescription in order to obtain their medication. This suggests that prescribers may be able to influence patient adherence with something as simple as authorizing more refills when they write prescriptions.

Weak pipelines, patent expirations, tight formulary control and curtailed pricing power have taken away the traditional big pharma growth levers. Improving medication adherence offer the last, best hope for big pharma revenue growth because it means more sales to existing users and a greater chance that the drugs will improve outcomes. That’s why this information is likely to be of major interest to pharma companies.

On the other hand the study reminds me of some inconvenient truths about medication adherence and the business models of analytics companies such as SDI. In particular:

  • The only medication adherence programs that seem to generate a positive return on investment are low tech, low cost. Despite the investment by big pharma companies in a variety of patient support programs, devices, psychographic profiling and so on, the only adherence approach with a consistenly positive return on investment has been sending refill reminder letters from pharmacies (typically sponsored by the pharma companies). The other, fancier approaches are pretty cool and have some impact, but their incremental costs usually outweigh their incremental advantages. Granting additional refills on the initial prescription is an example of a cheap, workable program. Pharma reps just need to convey the point to physicians. It shouldn’t be too hard. (Although some docs probably write fewer refills to encourage patients to come back more frequently.)
  • SDI used “anonymized patient level data” (APLD), which relies on matching individual patients to prescribers and tracking them over time. SDI uses matching algorithms to try to figure out which patient is which. Several companies including IMS, NDC (acquired by Wolters Kluwer) and Verispan (which SDI recently acquired) each sank tens of millions of dollars into building APLD businesses. Although APLD is a neat idea that represents a real improvement over the traditional IMS metrics, it’s been hard for the data companies to recoup their investments. Insights like the one described in this study are interesting, but once the information is out there there’s no real need to pay SDI to do the analysis again and again. So companies like this end up doing one-off studies for tens or hundreds of thousands of dollars. Meanwhile everyone can apply the “more refills is better” insight without paying SDI or anyone else.
  • The serious money in pharmaceutical prescribing analysis is still made by IMS, because its data is used for sales force compensation. That information has value on an ongoing basis. There’s also great resistance to changing an established system that’s working because it impacts sales reps’ compensation.

 


Posted in Economics, Pharma | Comments Off

Rerun: Two views on the Avastin/Lucentis debate

August 21st, 2012 by David E. Williams of the Health business blog

The Health Business Blog is taking a break this week, and re-running some posts from August 2008. If you’d like to comment, please do so on the original post.

Regular readers remember last year’s Avastin/Lucentis debate here on the Health Business Blog. To recap: the drugs are essentially the same and they’re made by the same company. Avastin is a cancer drug and Lucentis is used in the eye. Compounding pharmacists found a way to repackage Avastin into the much smaller dosages for ophthalmic use, thus making an ~$60-80 Avastin equivalent to a ~$2000 Lucentis dose. The manufacturer, Genentech, found itself caught in the middle.

In my view, drugs should be priced based on value, not dosage. Genentech deserves a lot more than $80 for an effective treatment for macular degeneration.

There are contrasting views on this topic on the two sides of the Atlantic, but the perspectives may surprise you.

Britain’s National Institute for Health and Clinical Excellence, which is known for its tough stance on expensive drugs, recommended the drug be freely available to U.K. residents, with the country’s National Health Service paying for 14 injections of the drug in each eye…

“Lucentis is an expensive drug, costing more than £10,000 ($18,386) for each eye treated,” Andrew Dillon, chief executive of the National Institute for Health and Clinical Excellence, said in a statement. “But that cost needs to be balanced against the likely cost savings. It has been estimated that the costs related to sight impairment for patients treated with Lucentis are around £8,000 cheaper than for patients who receive best supportive care over a 10 year period,” he said.

  • Meanwhile in the US, today’s Boston Globe (Study of 2 drugs places spotlight on Genentech) puts Genentech on the hotseat, blaming the company for its understandable reluctance to contribute funding to an Avastin v. Lucentis study for macular degeneration and predicting that Medicare will refuse to pay more for Lucentis:

What does a company do when there’s anecdotal evidence two of its drugs are equally effective in treating a leading cause of blindness in the elderly – one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

The Globe also predicts that Medicare will refuse to pay more for Lucentis:

An internal memorandum from congressional aides to the Senate Aging Committee’s chairman, Herb Kohl, Democrat of Wisconsin, recommends that lawmakers consider urging Medicare officials to pay no more for one drug than the other when it comes to treating the eye disease.

Medicare’s contractors already have authority to pay the same amount for items that achieve much the same result – such as hormones used to treat prostate cancer.

If the drugs are shown to work comparably, “it would surprise me if the contractors did not quickly use that concept,” said Dr. Steve Phurrough, director of coverage and analysis at the Centers for Medicare and Medicaid Services.

This is a complicated topic. I’m sympathetic to patients, physicians and payers who want access to low-cost, effective treatments. But Genentech deserves to earn a return on its investment from this impressive drug. I also know for a fact that the beating Genentech is taking on Lucentis is discouraging development of new treatments for macular degeneration.


Posted in Economics, Pharma, Policy and politics | Comments Off

Rerun: Are prescription drugs going the way of Napster, YouTube and iTunes?

August 20th, 2012 by David E. Williams of the Health business blog

The Health Business Blog is taking a break this week, and re-running some posts from August 2008. If you’d like to comment, please do so on the original post.

The distribution of prescription pharmaceuticals is beginning to take on some of the characteristics of online videos and music. Traditionally, access to prescriptions works as follows:

  1. Patient has a problem
  2. Patients sees his/her physician
  3. Physician diagnoses problem and writes prescription
  4. Patient takes prescription to traditional pharmacy or PBM-owned mail order company
  5. Pharmacy fills prescription with a drug manufactured by an FDA-regulated brand name or generic pharmaceutical company
  6. Patient takes medication
  7. If patient needs more medication after initial prescription and refills are exhausted, patient requests renewal from physician and repeats steps 4 to 7

But steps 2 through 7 are breaking down. Instead of seeing their physicians, increasing numbers of patients are either going directly online to order from pharmacies or are borrowing pills from friends and family who’ve received prescriptions. According to MedPage Today (Adults Commonly Share Prescription Drugs with Friends and Family) almost 30 percent of adults reported sharing prescription medications with others. Younger people are the most likely to share.

Meanwhile, shady web-based pharmacies that don’t require prescriptions and often sell counterfeit drugs are becoming increasingly sophisticated and impressive. MarketMonitor estimates that about 1000 shady pharmacy sites generate an average of 100,000 hits per day each and that such pharmacies spend about $25 million per year on search advertising. An acquaintance who works in the pharmaceutical security business told me that these pharmacies aren’t what they used to be. In fact they are adopting marketing and customer service best practices that are used by legitimate vendors. Rather than going for a quick score, the web-based companies are looking for repeat business and word-of-mouth referrals by providing products that work, offering easy-to-navigate websites and low prices.

This isn’t quite the same as what’s happened in the field of digital music and video, but there are similarities:

  • The intellectual property violators (e.g., Napster, YouTube, shady pharmacies) have made it easier and more convenient for consumers to get what they want –either for free or cheaply
  • Traditional players have had a hard time reacting (e.g., the big music companies, the big pharma companies). In music this has led to a major loss in sales and it’s also meant that the record labels have been willing to sell online. The emergence of DRM-free music downloads is due to the existence of free –though illegitimate– alternatives. It’s also allowed iTunes to gain leverage over the record companies

There are some important differences, though:

  • Unlike digitial music files, counterfeit pharmaceuticals aren’t exact copies of the originals –and it’s much harder to tell the difference
  • The existence of insurance and general acceptance of the doctor’s role in prescribing means there’s less demand for free, presciptionless drugs
  • Pharmaceuticals are physical products, so it is possible to secure the supply chain

Still I wonder whether some of the shady websites will end up going legit (like Napster) and whether pharma companies will be forced to react (e.g., by pushing for OTC clearance of lifestyle drugs that are still on-patent or by bundling services in with their products).


Posted in Culture, Economics, Pharma | Comments Off

Medtronic’s doctor centered approach helps patients, too

August 16th, 2012 by David E. Williams of the Health business blog

As I described on Tuesday, orthopedic device makers are putting more control in the hands of patients to make adjustments that used to be handled by physicians. It’s more convenient for patients, but the key to the business model is that such moves reduce the demands on physicians, who otherwise would have to participate in these low-margin, unexciting activities. I mentioned cardiology as another field where device makers think similarly. And I was rewarded today when a colleague showed me an article that illustrates my point perfectly.

When patients with implanted cardiac devices go to the emergency room –even for something unrelated to their heart– they end up having to wait around a long time to have their device checked by someone with special expertise. That has to be done in person and is a real pain in the neck  for the patient, especially when it happens on a night, weekend or rural area. The new service included a wand that can pick up data from the device, transmit it to an expert wherever that person is, and integrate the information into the electronic medical record of the hospital and/or physician office.

Don’t get me wrong. Medtronic definitely cares about the patient. But the primary economic motivation for this technology is to take cost and hassle off of physicians and clinics that have to deal with this after-sales service. You can bet that a doctor who gains the benefit of CareLink Express will look favorably on the opportunity to implant more Medtronic devices in the future, compared to a manufacturer who doesn’t have this offering.


Posted in Devices, Economics | No Comments »

Why Nobody Believes the Numbers: Al Lewis takes on Milliman and Mercer (transcript)

August 10th, 2012 by David E. Williams of the Health business blog

This is the transcript of my recent podcast interview with Al Lewis. If you’re looking for a productive post you’ve come to the right place.

David E. Williams: This is David Williams, cofounder of MedPharma Partners and author of the Health Business Blog. I’m speaking today with Al Lewis. He’s president of the Disease Management Purchasing Consortium and he’s also the author of a new book: Why Nobody Believes the Numbers: Distinguishing Fact from Fiction in Population Health Management.

Al, thanks for joining me today.

Al Lewis: Thanks for having me, David.

Williams: It’s a provocative title for the book. Tell me a little bit more about the thesis of this book is and share a few key takeaways.

Lewis: The thesis of the book is that the entire valued-added services industry in the managed health care sector, including for self-insured employers, is just rife with incompetent measurement of outcomes. As a result of this incompetent measurement of outcomes, massive amounts of money get misallocated to programs of extremely dubious value.

However, the good news is that if in fact you can measure the outcomes correctly, you can probably reduce the amount of money you spend on these programs while getting a modest but real savings and improvement in health for your employees.

The three biggest takeaways of the book are; number one, that most of this stuff is done incorrectly; number two, you can do this correctly, you can measure your outcomes correctly using what I call ‘ingredients you already have in your kitchen’. You don’t have to do anything fancy involving statistics or actuaries or anything, simply the fifth grade math that you learn to get an answer, which is reasonably valid. And number three, when you get that valid answer, you may find that you saved small amounts of money and that you’ve made some noticeable improvements in the health of your population, but it will not solve your problem of increasing cost year over year.

Williams: There is a group out there called the Care Consortium Alliance. They have guidelines for measuring outcomes, but I take it that you don’t think too highly of their approach even though it’s fairly well accepted in the industry.

Lewis: Math is not a matter of opinion, David. And that’s the beauty of it. It’s not ‘he said, she said’. It’s proof versus disproof. So it’s not a question of whether I think highly of their guidelines. The question is whether their guidelines are valid. And I actually found a major mistake in their premise that pre-post measurement is valid. I proved the mistake in the book.

But people should not be scared away by the word “proof” in the book; this is all fifth grade arithmetic. In fact, I actually dedicated the book to my fifth grade math teacher. I said, “To my fifth grade math teacher for apparently doing a better job than the other kids’ fifth grade math teachers.”

The mistake causes savings to be overstated any time a pre-post measurement is used. Rather than get it in to a shouting contest in math, which is not appropriate in math, I simply said, “This is the answer and if anybody can find a real or hypothetical situation with numbers,  where the guidelines in the book will give a wrong answer and the Care Continuum guidelines will get the correct answer, I will pay that person $10,000.” Well, guess what, the $10,000 is still sitting happily in my bank account.

Williams: You mentioned actuaries. And of course there are big groups like Milliman and Mercer that are active in the measurement business. They have actuaries, they have a lot of people that made it even further than the fifth grade. But you do take issue with a lot of their work. You say that many of their findings are actually impossible.

Lewis: Yes.

Williams: They’re really that out of line?

Lewis: Yes. “Impossible” is the correct  word. Once again, that’s the beauty of math. The numbers either add up or they don’t. It’s not arguable. In the case of Milliman, they found savings for North Carolina Medicaid for their children’s admissions that were more than twice as high as the amount of money that the State of North Carolina spent on children’s admissions.

And by the way, that number did not fall over the period in question, so Milliman was actually impossible in two different ways.

Then Mercer, well, they had several examples of impossibility in the book including in the State of Georgia where they found mathematically impossible savings. It turned out that the vendor, APS Healthcare in this case, later agreed to return Georgia’s fees because they acknowledged not making the outbound phone calls.

So essentially, Mercer was able to find mathematically impossible savings where nothing was actually done to achieve those savings. So am I very popular with Milliman and Mercer? No. In the case of Milliman, I offered them a $50,000 bet to take their report and my report and submit it to Harvard University and have Harvard University say which one is valid. I have not heard back from them.

Williams: What do you suppose leads to these sorts of very large errors and impossible results? I mean, you’re picking on some programs like North Carolina that are fairly well known and often touted as successful. Is it just a matter of not hiring the right people, or vendors are saying what people want to hear. What’s going on?

Lewis: That’s an excellent question and if you had asked me a few weeks ago, I would have said they’re telling the consultants what to tell them back. Having talked to Milliman, having talked to North Carolina, first, the North Carolina people have been complete adults about this whole thing, which frankly, is more than I was at first.

And I genuinely think that they do want to find the right answer. It’s hard for them to accept that perhaps the program has not saved money because they’re very passionate about it. And frankly, if I were in Medicaid and I could move to any of the 50 states, I’d probably move to North Carolina. But that’s a lot different from saying that a program saved money.

Williams: Why is it that you could have this level of error?

Lewis: Well, in disease management, you get it because the pre-post guidelines are mathematically invalid and you can literally do nothing except measure year over year using  the recommended algorithm and you’ll save money.

I actually recommend doing that year over year in a program where you do not have disease management to see how much costs go down without doing anything. And I give a couple of examples of where that happens in real life; Illinois Medicaid is an example in my book.

In disease management, all you need to do is follow the guidelines and you’ll make mistakes. In wellness, the mistakes are just massive. I say in the book that wellness is five years behind disease management in measurement which is like being five years behind Iraq in democracy.

Number one, you can’t compare participants to non-participants and have that be a valid answer. If I split the population, if I say to people I’ll pay you $100 and I’ll teach you how to compete in a triathlon, the people who sign up for that, even if you do nothing, will have lower cost than people that don’t participate.

That’s obvious in the case of the triathlon, but it’s true everywhere. It’s just not recognized. So number one, they compare participants to non-participants. Number two, all the time they’d say we took the high-risk people and we did all the stuff with them and the risks went way down.

Well, Dee Edington who  spent more time studying the measurement of risk than probably everybody else on Earth combined, has noted that if you do nothing to the high-risk people that their risk factors would fall –I may be misquoting a little– by 30 percent over the next two years or something like that. That doesn’t mean the people are getting healthier, that simply means that the lower-risk people are becoming higher risk. But they’re not counted, so it doesn’t matter.

So you have participant versus non-participant bias, you have a regression to the mean in risk factors, and the third thing you have is just the simple unwillingness or inability to step back and say, “Are these findings even possible? Are they mathematically within the range of possibility?” And the answer most of the time is no.

I mean, they say, well, cost went down by 30%. Well, for cost to go down by 30% through a wellness program, you’d have to eliminate essentially every single health-sensitive hospitalization, and health-sensitive ER visit in the entire population in your company.

So you think somebody would say, “I wonder if we’ve reduced the number of heart attacks or the number of diabetic events in our population in the last couple of years.” No one ever asks that very basic question.

You’re trying to improve the health of people’s hearts. Somebody should find out if in fact the number of unhealthy heart events went down.

Williams: Let’s jump coasts and go from the public to the private sector for a minute. I want to ask you about Safeway, which is a well known, highly touted company in terms of the approaches they’ve taken on trying to get their health care cost under control and improve the health of their employees. Is that one that’s robust?

Lewis: Well, I had never challenged Safeway myself because it was so well publicized and everybody cited it so much that I didn’t think it could possibly have been wrong. And then I just read in the New England Journal of Medicine, a study that in fact showed that Safeway’s zero trend, which was due to many things that they did in benefit design, predated their wellness program by three whole years.

So despite the fact that Congress appears to have relied on Safeway numbers when they put wellness incentives into the Accountable Care Act, Safeway’s savings were emphatically not due to wellness.

So you have two situations here; one in the public sector, North Carolina Medicaid, and one in the private sector, Safeway, where entire government policies have been largely based on two sets of outcomes that no one bothered to challenge. And then when you look at them, they turn out to be incorrect.

Williams: On the one hand, I can understand how purchasers of wellness and disease management services and policy makers would be pleased with your work. On the other hand, there is a huge need to save money and improve population health. So I wonder, does anything actually work?. I mean, are we all pointing in the wrong direction here?

Lewis: Well, there is a line in the book that says that everything in life has an 80-20 rule. Meaning, 20 percent of your effort gets you 80 percent of your result. In health care, the 80-20 rule is that 80 percent of the time there is no 80-20 rule.

So you can’t push a button in health care, or two buttons, or three buttons and have costs go down. All the initiatives that are being discussed at the public and a private level, except for very simple things like pushing the money back on to the consumer, are only going to make marginal reductions in savings.

And let’s look at wellness now, in particular. Let’s take the case of Greece and Germany. Germany is very productive and Greece isn’t very productive. So if I said to you all we have to do is have the Greeks be as productive as the Germans and their economy will be saved, and not only that but we were able to pay 20 Greeks who were willing to go to Germany and work there and have their productivity go way, way up. Therefore, Greece can be like Germany.

You would say that’s ridiculous. But in fact, that’s the way wellness works. They start with a premise that healthy people are more productive than unhealthy people, which is true. Nobody would argue with that. Then they find a few unhealthy people who became healthy and they say anybody can become healthy. But in fact, you can’t make Greece into Germany. Only a few people are going to migrate from unhealthiness to healthiness.

You can pay everybody in Greece all you want to try to be more productive, but they’re not going to turn into Germans. Likewise, in wellness, you can make all the incentives you want for unhealthy people and very few of them are going to be essentially paid off to become healthy.

Williams: Final question, Al, I want to know whether you consider yourself to be an optimist or a pessimist?

Lewis: I am neither. I suspect that over time, health care will increase at the rate of GDP plus a little bit beyond that to account for aging and better treatments. And this is not such a bad thing if in fact you have better treatments. I myself have cancer and it’s responded extremely well to the type of better treatments that were not available 20 years ago, when I therefore wouldn’t have spent any money on them.

So that’s not a bad thing. By and large, I’m not pessimistic about the future for our health care. A lot of the extra spending is going to be for treatments that simply were not available awhile back that keep people like me healthy and productive.

Williams: I’ve been speaking today with Al Lewis from the Disease Management Purchasing Consortium. We’ve been talking about some of the interesting findings from his new book which is called Why Nobody Believes the Numbers: Distinguishing Fact from Fiction in Population Health Management.

Al, thanks for joining me today.

Lewis: Thank you for having me, David.


Posted in Economics, Podcast | 2 Comments »

Why Nobody Believes the Numbers: Al Lewis takes on Milliman and Mercer

August 7th, 2012 by David E. Williams of the Health business blog

Disease Management Purchasing Consortium President Al Lewis has never been one to mince words. So it’s no surprise that he comes out swinging in his book, Why Nobody Believes the Numbers: Distinguishing Fact from Fiction in Population Health Management.

In this podcast interview he summarizes some of the provocative points from his book:

  • The widely used Care Continuum Alliance guidelines are invalid
  • Milliman and Mercer make massive mistakes in measurement –and many of their claims are simply “impossible”
  • Some entities that think they have saved hundreds of millions of dollars from disease management and wellness programs don’t appear to have saved anything at all

Al is putting his money where his mouth is, offering thousands of dollars to those who can prove him wrong.

Listen carefully and you’ll also hear some observations about Iraq, Greece and Germany.


Posted in Economics, Podcast | 2 Comments »

Did pharma reps win by losing their overtime pay lawsuit?

June 21st, 2012 by David E. Williams of the Health business blog

Pharmaceutical reps lost their class action lawsuit seeking overtime pay. Dow Jones (FINS: Losing Overtime is a Win for Drug Reps) asserts that, “the ruling may have actually saved the jobs of thousands of pharmaceutical sales reps.” The argument: if drug companies had to pay reps a big settlement, they would have instituted another round of layoffs as a response. That’s at least what two executives from pharma recruiting companies said.

I’m not really buying it. Despite relatively hard times recently, big pharma companies are generally well capitalized and able to pay whatever they owe. Any ruling against the companies seemed unlikely to dramatically affect future costs, because the companies would have just adjusted their policies and pay formulas to conform. Therefore I don’t think widespread layoffs would have ensued.

All in all, I’m not sure recruiters were the best source for this story!

 


Posted in Economics, Pharma | No Comments »

With health care restraining costs, can higher education be far behind?

May 16th, 2012 by David E. Williams of the Health business blog

Health care cost containment is no longer a fantasy. While health expenditures have increased much faster than GDP for many years a combination of factors is likely to bring that trend to an end: hard economic times, cost shifting to patients, and increased consumer understanding that more care isn’t always better.

The one major sector of the economy that’s as dysfunctional as health care is higher education, where costs have also ballooned. Now that student debt is getting the attention it deserves and politicians are beginning to turn their focus to college costs, there will be pressure for creative solutions. I’m encouraged that leading universities like Harvard and MIT are starting to put classes online.

It will be a long, long time before this movement disrupts the business model of Harvard and MIT themselves. That’s because there’s a large and –thanks to the emergence of China– growing surplus of people willing to pay full freight for the privilege of a Harvard or MIT education. It can also be worthwhile to go to such schools to make connections and to have a rich cultural and social life. But schools of much more middling quality charge nearly the same tuition as the choicest universities, and they should be very worried indeed. Would you pay $200,000 for four years at Generic College when you could take online classes at Harvard and MIT and pay a few thousand dollars for a certificate indicating your completion of the classes?

I hope the Harvard/MIT experiment progresses rapidly and that lesser schools find creative ways to respond that increase the value that students receive.


Posted in Economics | 1 Comment »

Dude, you’re getting a raise! (If health care costs can be contained)

May 3rd, 2012 by David E. Williams of the Health business blog

Employees grumble every year when their employers make them pay more toward their health insurance costs and/or increase co-pays and deductibles. But most of the time employers absorb the bulk of the financial hit and only pass along a fraction of the overall increase. One result has been a stagnation in real wages, as a higher and higher percentage of employment costs come in the form of health care. This isn’t visible to the typical person, but the fact is the health care industry has sucked up essentially all the money available for raises.

What that means is that as health care costs are brought under control –as I firmly believe they will be– there’s an opportunity for middle class Americans to resume an upward trajectory in real wages. MIT economist Jonathan Gruber has picked up on this theme in a new study for the Blue Cross Blue Shield Foundation of Massachusetts.

I believe that Massachusetts is on the cusp of taming the health care cost beast, a situation made possible by RomneyCare’s near-universal coverage followed by innovative efforts of private health plans and providers, plus the threat of state government intervention. While out-of-state ideological critics caricature the Massachusetts approach, they may soon be treated to the specter of the state outshining others in real wage growth, in a way that doesn’t hurt the competitiveness of our employers.


Posted in Economics, Policy and politics | 2 Comments »

« Previous Entries Next Entries »